Opinion|Videos|January 3, 2025
Clinical Perspectives Selecting 2L Treatment Options in R/R FL: Chemoimmunotherapy vs Lenalidomide Combinations in Relapsed Disease
Panelists discuss how their treatment approaches in the second-line (2L) setting for relapsed or progressive follicular lymphoma (R/R FL) are influenced by factors such as the duration of response to first-line therapy, tumor burden, and symptomatology, while also exploring the use of chemoimmunotherapy, lenalidomide combinations, and anti-CD20 monotherapy in clinical decision-making.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- For those with progression of disease, what is your treatment approach in the 2L setting? How do you factor in the duration of response to 1L therapy in selecting your 2L option as well as patient factors such as those with high tumor burden and/or symptomatic disease?
- How often are you utilizing chemoimmunotherapy with an anti-CD20 in the 2L setting? What percentage of your patients are receiving a bendamustine-based or cyclophosphamide-based regimen in the 1L setting?
- What is your treatment approach in selecting lenalidomide in combination with anti-CD20 vs anti-CD20 monotherapy?
- What patient and/or disease factors do you consider?
- Please feel free to comment on any differences and/or similarities in practice when selecting lenalidomide monotherapy vs in combination with anti-CD20 vs anti-CD20 monotherapy.
Advertisement
Related to this article
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
A 3-year, $225K award will focus on improving quality of life for patients living with long-term effects of cancer treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
3
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5